Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

COVID-19

R&D

PS100P. Development of an alarmin fingerprint for diagnosis/prognosis of cancer from plasma samples

The family of calcium binding proteins S100, also called Alarmines, is involved in a large number of intracellular and extracellular functions, which include the control of protein phosphorylation, transcription factors, in Ca2+ homeostasis, the dynamics of the cytoskeleton components, enzymatic activities, cell growth, differentiation, and inflammatory response. They belong to the group of molecules with a molecular pattern associated with damage (DAMPs; Damage-associated molecular pattern).

There are at least 21 different types of S100 proteins, and under physiological non-pathological conditions, most family members are not expressed, or are expressed at very low levels, while their overexpression is involved in multiple neoplastic processes, such as proliferation, survival, invasion, tumor growth, angiogenesis and metastasis. Overexpression in neoplastic tissues implies their release in blood, which allows its monitorization after tumor resection or throughout patient’s treatment.

The aim of the project is to develop a molecular signature of alarmines (S100A4, S100P, S100A7 and S100A8/A9) from blood samples from patients with breast cancer and non-small cell lung cancer (NSCLC), and to analyze its participation in various oncological processes (tumor evasion of the immune system and resistance to immunotherapy, establishment of pre-metastatic niches, resistance to chemotherapy and recurrent biological therapy, etc.). Correlation of results with other clinical parameters will allow us to establish a personalized prognosis of patients to guide their future treatment.

In order to successfully achierve the bjectives of the project, Atrys will outsource the services of the Health & Biomedicine Unit laboratory of the LEITAT technology center.

This project has the support of CDTI for its financing through the call for Cervera Aids for Technology Centers

2019-2022